69 replies to this topic

[shawn]

Found this:
http://www.methylene...om/contacts.php
Dream in blue

Methylene blue is finally available in a safe, stable format without heavy-metal contamination, all thanks to a four-year R&D commitment from Provence Technologies.
http://www.worldphar...12_provence.htm

Looks to be better than the other suppliers who all seem to be from China with definite impurity problems even in the pharma-grade, but I couldn't see anywhere on their site if they had a product for sale yet.

[rwac]

Methylene blue is finally available in a safe, stable format without heavy-metal contamination, all thanks to a four-year R&D commitment from Provence Technologies.
http://www.worldphar...12_provence.htm

It really sounds like it's going to be prescription only.

[shawn]

It figures.....lock up the medicine cabinet to keep those irresponsible self-medicaters from fooling around....sheesh.
Everything that seems to prove efficacy, same thing.
But we are allowed to have all the low-grade, in-effective crap we wish, and all the toxic food we can stuff down our necks .

So does anyone know of a source of this which they make effort at removing the contaminates which isn't prescription.

[qemist]

Clin-Alert October 31, 2003 vol. 41 no. 20 1-8:
METHYLENE BLUE No. 276
Neurological Events
A 60-year-old female patient developed an adverse neurological event following the use of intravenous
methylene blue for parathyroidectomy. The patient’s medications included fluoxetine, coproxamol, and
beclomethasone nasal spray. Preoperatively to a parathyroidectomy, a methylene blue infusion (7.5 mg/kg)
was administered. The patient vomited once and on arrival in the anesthetic room, looked very blue but
showed no abnormal behavior. Shortly after arrival in recovery, the patient was noted to have rotational nys-
tagmus and dilated pupils that were unreactive to light. Thirty minutes later, the patient began to display rigid,
jerky movements of all 4 limbs and remained very agitated over the subsequent 2 hours with a fluctuating
Glasgow Coma Scale (GCS) of 7 to 10. The patient had increased tone in all 4 limbs and bilateral up-going
plantar reflexes, was sweating profusely, and was flushed above the shoulders. An arterial blood gas re-
vealed a respiratory acidosis. After 4 days, the patient had made a full recovery, with a normal MRI scan.
The authors concluded that this patient most likely experienced an adverse event to intravenous methy-
lene blue. They suggested that intravenous methylene blue excited the patient, and by its rapid elimination
into the stomach and urine, produced transitory gastrointestinal and urinary irritation. Toxic symptoms either
subsided or resolved in 24 to 48 hours.
Methylene Blue [“Methylene Blue”]
Martindale SJ & Stedeford JC (Bristol Royal Infirmary, Bristol BS2 8BJ, UK; Neurological sequelae following methylene blue injection
for parathyroidectomy. Anaesthesia 58(10):1041–1042 (Oct) 2003

[rwac]

Preoperatively to a parathyroidectomy, a methylene blue infusion (7.5 mg/kg) was administered.

Um, we're talking about doses of the order of a few mcg/kg.
About three magnitudes smaller than the dose you're talking about.

[AgeVivo]

Methylene Blue's potential effects against Alzheimer Disease could be explained by increased clearance of abnormal proteins in the brain: "MB increases (...) activities of the proteasome in the brain".

Brain Pathol. 2010 Jul 27. [Epub ahead of print]


Methylene Blue Reduces Abeta Levels and Rescues Early Cognitive Deficit by Increasing Proteasome Activity.
Medina DX, Caccamo A, Oddo S.

Department of Physiology and The Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, San Antonio, TX.


Abstract
Abstract Promising results have emerged from a phase II clinical trial testing methylene blue (MB) as a potential therapeutic for Alzheimer disease (AD), where improvements in cognitive functions of AD patients after 6 months of MB administration have been reported. Despite these reports, no preclinical testing of MB in mammals has been published, and thus its mechanism of action in relation to AD pathology remains unknown. In order to elucidate the effects of MB on AD pathology and to determine its mechanism of action, we used a mouse model (3xTg-AD) that develops age-dependent accumulation of Abeta and tau and cognitive decline. Here, we report that chronic dietary MB treatment reduces Abeta levels and improves learning and memory deficits in the 3xTg-AD mice. The mechanisms underlying the effects of MB on Abeta pathology appears to be mediated by an increase in Abeta clearance as we show that MB increases the chymotrypsin- and trypsin-like activities of the proteasome in the brain. To our knowledge, this is the first report showing that MB increases proteasome function and ameliorates AD-like pathology in vivo. Overall, the data presented here support the use of MB for the treatment of AD and offer a possible mechanism of action.

PMID: 20731659 [PubMed - as supplied by publisher]

[maxwatt]

Preoperatively to a parathyroidectomy, a methylene blue infusion (7.5 mg/kg) was administered.

Um, we're talking about doses of the order of a few mcg/kg.
About three magnitudes smaller than the dose you're talking about.

60 mcg is the dose for the effects we're talking about. This is the same order of magnitude as a 2X homeopathic dilution.

Edited by maxwatt, 28 August 2010 - 07:57 PM.

[rwac]

60 mcg is the dose for the effects we're talking about. This is the same order of magnitude a 2X homeopathic dilution.

He's talking about a dose of 7.5 mg/kg, 60 mcg would be <1 mcg/kg, assuming 75 kg weight ?

Edited by rwac, 28 August 2010 - 03:43 PM.

[ampa]

I ordered MB from 2 different sources and started off at about 1/1000 the dosage recommended by geddarkstorm here. After about 30 min i got a metabolic rush, lasting also for ~30 min which subsided and recurred with food intake. Marked Nervousness and Excitablity, Heachache for the next day. Probably some allergic response/enzymatic reaction?

Methylene Blue is a monamine oxidase inhibitor (MAOI), which if combined with serotonergic agents (i.e. antidepressants) may precipitate serotonin syndrome. (Google methylene blue, MAOI, serotonin syndrome.)

Edited by ampa, 04 September 2010 - 01:41 AM.

[lynx]

Methylene Blue's potential effects against Alzheimer Disease could be explained by increased clearance of abnormal proteins in the brain: "MB increases (...) activities of the proteasome in the brain".

Brain Pathol. 2010 Jul 27. [Epub ahead of print]


Methylene Blue Reduces Abeta Levels and Rescues Early Cognitive Deficit by Increasing Proteasome Activity.
Medina DX, Caccamo A, Oddo S.

Department of Physiology and The Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, San Antonio, TX.


Abstract
Abstract Promising results have emerged from a phase II clinical trial testing methylene blue (MB) as a potential therapeutic for Alzheimer disease (AD), where improvements in cognitive functions of AD patients after 6 months of MB administration have been reported. Despite these reports, no preclinical testing of MB in mammals has been published, and thus its mechanism of action in relation to AD pathology remains unknown. In order to elucidate the effects of MB on AD pathology and to determine its mechanism of action, we used a mouse model (3xTg-AD) that develops age-dependent accumulation of Abeta and tau and cognitive decline. Here, we report that chronic dietary MB treatment reduces Abeta levels and improves learning and memory deficits in the 3xTg-AD mice. The mechanisms underlying the effects of MB on Abeta pathology appears to be mediated by an increase in Abeta clearance as we show that MB increases the chymotrypsin- and trypsin-like activities of the proteasome in the brain. To our knowledge, this is the first report showing that MB increases proteasome function and ameliorates AD-like pathology in vivo. Overall, the data presented here support the use of MB for the treatment of AD and offer a possible mechanism of action.

PMID: 20731659 [PubMed - as supplied by publisher]

To me, this seems like the key to why any company would be interested in MB. If Abeta is the problem in AD, then increasing proteasome activity is key. Yet, let us consider an alternate possibility--general waste removal becomes impaired over time in all cells. So rather than telomere shortening the more logical explanation of senesence would be impaired wasted removal.